记者丨闫硕 编辑丨季媛媛 张星 1月27日，新修订的《中华人民共和国药品管理法实施条例》（简称《条例》）正式公布，共9章89条，将于2026年5月15日起施行。此次23年 来首次全面修订，亮点突出：明确4条药品加快上市通道，首次设立儿童药、罕见病药市场独占期…… 药品安全关系人民群众身体健康和生命安全。现行《条例》于2002年公布施行，经过3次部分修改，对保证药品管理法有效实施、保障人民群 众用药安全发挥了重要作用。2015年我国开始实施药品监管改革，2019年对《条例》的上位法《药品管理法》作了全面修订。此次对《条例》 修改的条款达到90%以上，除了第一条以《药品管理法》作为立法依据的条款没有修改外，其余条款均有调整或者修改。 上海市卫生和健康发展研究中心主任金春林向21世纪经济报道记者指出，本次修订将引发我国医药产业供给侧的深刻变革，倒逼国内医药企业 实现转型升级。这将推动产业发展模式从低水平的Fast-follow（快速跟进），转向高水平的原始创新，也促使企业竞争格局从本土市场角逐， 升级为全球化市场竞争。 上海德禾翰通律师事务所律师张晓欣对21世纪经济报道记者表示，此次修订将过去多年的药品审评审批改革 ...

1月27日，新修订的《中华人民共和国药品管理法实施条例》（简称《条例》）正式公布，共9 章89条，将于2026年5月15日起施行。 此次23年来首次全面修订，亮点突出：明确4条药品加 快上市通道，首次设立儿童药、罕见病药市场独占期…… 药品安全关系人民群众身体健康和生命安全。现行《条例》于2002年公布施行，经过3次部分 修改，对保证药品管理法有效实施、保障人民群众用药安全发挥了重要作用。2015年我国开始 实施药品监管改革，2019年对《条例》的上位法《药品管理法》作了全面修订。 此次对《条 例》修改的条款达到90%以上 ，除了第一条以《药品管理法》作为立法依据的条款没有修改 外，其余条款均有调整或者修改。 上海市卫生和健康发展研究中心主任金春林向21世纪经济报道记者指出，本次修订将引发我国 医药产业供给侧的深刻变革，倒逼国内医药企业实现转型升级。这将推动产业发展模式从低水 平的Fast-follow（快速跟进），转向高水平的原始创新，也促使企业竞争格局从本土市场角 逐，升级为全球化市场竞争。 上海德禾翰通律师事务所律师张晓欣对21世纪经济报道记者表示，此次修订将过去多年的药品 审评审批改革中的成熟政策上升 ...

Core Viewpoint - The company has received FDA approval for its self-developed cancer drug KC1086, marking a significant milestone in its strategic development and potential for future product pipeline expansion in oncology treatment [2]. Group 1: Drug Development - KC1086 is a small molecule inhibitor targeting KAT6, intended for treating advanced recurrent or metastatic solid tumors, with preclinical studies showing over 90% tumor suppression in ER+/HER2 breast cancer models [2]. - The clinical trial for KC1086 is progressing smoothly, having received regulatory approval from the National Medical Products Administration in June 2025 and enrolling its first participant in August 2025 [2][3]. - The company is also advancing other projects, including KC1036 for advanced esophageal squamous cell carcinoma and ZY5301, which is in the registration application phase [3]. Group 2: Financial and Tax Benefits - As of Q3 2025, the company's R&D expenses reached 32.8 million yuan, with a focus on unmet clinical needs in various therapeutic areas [3]. - The company has been re-certified as a high-tech enterprise, allowing it to benefit from a reduced corporate tax rate of 15% for three consecutive years from 2025 to 2027, providing a stable tax environment for R&D investments [4]. Group 3: Investment Outlook - The company is projected to have EPS of 0.88 yuan, 1.11 yuan, and 1.33 yuan for the years 2025 to 2027, with corresponding dynamic P/E ratios of 45.67, 36.09, and 30.16 [5]. - As a leading player in the blood coagulation agent sector, the company is expected to achieve diverse innovation outcomes through ongoing R&D and product introductions, maintaining a buy rating [5].

Core Viewpoint - The approval of KC1086 by the FDA marks a strategic milestone for the company, showcasing its innovative research and development capabilities [1] Group 1: Product Development - KC1086's FDA approval indicates the company's potential to enhance its product pipeline in the treatment of malignant tumors, which could significantly boost future performance [1] - The overall progress of the company's research pipeline is on track, with research expenses reaching 32.8 million yuan by Q3 2025 [1] - Multiple innovative drug projects, including KC1101 and KC5827, are entering the preclinical development stage, indicating a continuous enhancement of the product pipeline [1] Group 2: Recognition and Market Position - The company has been recognized as a high-tech enterprise, allowing it to continue benefiting from policy incentives [1] - As a leading player in the blood coagulation agent segment of the industry, the company is enriching its product pipeline through ongoing research innovation and product introduction [1] - The successful advancement of various research projects positions the company to potentially realize a diverse range of innovative outcomes in the future [1]

Core Insights - The National Medical Products Administration has approved the sodium hyaluronate eye drops submitted by Yangzhou Zhongbao Pharmaceutical Co., Ltd, enhancing the company's product pipeline in the ophthalmology sector [1][2] - Sodium hyaluronate is a natural polysaccharide known for its excellent moisture retention and lubrication properties, addressing the increasing prevalence of dry eye symptoms due to heightened screen time and electronic device usage [1] - The approval of this product not only provides a reliable solution for the domestic eye medication market but also offers consumers a convenient and safe option for self-medication [1] Company Overview - Yangzhou Zhongbao Pharmaceutical is a comprehensive pharmaceutical enterprise engaged in research and development, production, and marketing, with a product range covering cardiovascular, respiratory, ophthalmology, and health sectors [1] - The company has established a diversified R&D system, including innovative drug development, inhalation formulation technology platforms, and ophthalmic drug research platforms, showcasing its continuous innovation capabilities [1] - The company has received over 20 invention patent authorizations and has more than 30 ongoing projects, reflecting its robust innovation vitality [1] Recent Developments - In the past two years, Yangzhou Zhongbao Pharmaceutical has entered a concentrated harvest period for R&D achievements, with multiple new products successfully launched or passing the consistency evaluation for generic drugs [2] - The sodium hyaluronate eye drops are not the only product approved this year; the company has also received approvals for six other products, including inhalation solutions and injection liquids, demonstrating strong product pipeline development and continuous innovation [2] - Looking ahead, the company plans to leverage this product approval to increase R&D investment, optimize product structure, and develop more high-quality drugs that meet clinical and market needs, contributing to the "Healthy China" initiative [2]

Core Insights - Kangyuan Pharmaceutical has been recognized for its continuous R&D innovation capabilities, ranking 21st in the overall R&D strength and 1st in traditional Chinese medicine R&D strength at the "2025 PDI Pharmaceutical R&D Innovation Conference" [1] Group 1: R&D Achievements - Kangyuan Pharmaceutical has consistently increased its R&D investment, with R&D expenses as a percentage of revenue rising from 13.92% in 2022 to 15.85% in 2023, and projected to reach 16.79% in 2024 [1] - The number of R&D personnel has also grown, expected to reach 782 by 2024, accounting for 12.75% of the total workforce [1] Group 2: Strategic Initiatives - The company has been advancing its "one body, two wings" strategy and has established a "R&D generation, planning generation" model to enhance overall innovation capability and market competitiveness [2] Group 3: Product Development Pipeline - In the traditional Chinese medicine sector, as of Q1 2025, Kangyuan has several products in various stages of development, including 1 in NDA technical review, 2 in Pre-NDA, and 4 in Phase III clinical trials [3] - In the chemical drug sector, the company has 2 products in Phase III clinical trials and 3 in Phase II, targeting conditions such as Alzheimer's disease and idiopathic pulmonary fibrosis [3] - In the biopharmaceutical sector, following the acquisition of Zhongxin Pharmaceutical, Kangyuan has 4 biopharmaceutical innovations in clinical stages, including KYS202002A and KYS2020004A [3] Group 4: Modernization Efforts - As a traditional Chinese medicine enterprise, Kangyuan is promoting modernization through a comprehensive innovation system that includes "ancient text analysis and clinical evaluation" [4] - The company is also advancing the construction of intelligent extraction and formulation factories, utilizing industrial robots and big data analytics to improve production efficiency and quality control [4] - Kangyuan has set a timeline for the commercialization of biopharmaceuticals, aiming for market entry within 3 to 5 years [4]